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1. Introduction 
There is considerable interest in ruthenium(II) polypyridine 
complexes1-7 which have been investigated in the context of 
water splitting8, 9 and as sensitizers for dye-sensitized solar 
cells.10-15  These investigations are particularly relevant as the 
planet’s energy demands are an area of significant societal and 
scientific concern.16, 17  In exploring complexes for such 
applications, the stereochemical, electrochemical, and 
photophysical properties of ruthenium(II) polypyridine 
complexes are of particular interest.3, 5, 7, 18, 19  These can be 
tailored by altering the nature of the ligands coordinated to the 
metal centre.2, 7, 20-26 These changes to the archetypal chelating 
biheterocyclic ligand structure have led to new complexes 
displaying modified electrochemical and photophysical 
properties, and in turn new candidates for the noted applications. 
We have had an interest in a group of planar, highly 
conjugated heterocyclic compounds (Figure 1, (a)), 5-(2-
pyridyl)pyrazino[2,3-b]indolizine (1a), 5-(2-
pyridyl)indolizino[2,3-b]quinoxaline (1b), and 8,9-dimethyl-5-
(2-pyridyl)indolizino[2,3-b]quinoxaline (1c), that are effective 
chelating ligands for transition metal ions.27  Compounds 1a – 1c 
are electrochemically active and display several distinct 
absorption features through the visible range; derivatives 1b and 
1c give intensely purple colored solutions, while 1a gives a red 
solution consistent with its shorter wavelength absorption in the 
visible range.27  The complexes of the type [RuL(bpy)2]2+ and 
[RuL(dmb)2]2+ (where bpy = 2,2′-bipyridine; dmb = 4,4′-
dimethyl-2,2’-bipyridine; L = 1a – 1c) also show a number of 
characteristic redox potentials, and those complexes containing 
1b and 1c are black dyes. 
Other fused heterocyclic compounds with related cores (such 
as 2 and 3) have also been studied due to their unique structures, 
synthetic challenges, and potentially interesting biological 
properties (Figure 1, (b)).28-30  For example, variolin B is a 
natural product isolated from the Antarctic sponge Kirkpatrickia 
varialosai by the group of Blunt and Munro.31  Variolin B 
contains the pyrido[3′,2′:4,5]pyrrolo[1,2-c]pyrimidine skeleton 
4.30  Synthetic approaches developed by one of us32, 33 allows the 
convergent synthesis of variolin B, while alternative linear 
synthetic pathways have been reported.34-39 The chemistry and 
biological properties of variolin B and related derivatives have 
been reviewed.30 
As part of our ongoing work on heterocyclic compounds as 
ligands,26 we noted the structural similarities between the core of 
the variolins and compounds 1a – 1c.  This provoked us to study 
the biological properties of these fused heterocyclic compounds 
and to explore the synthesis of other derivatives.  Herein we 
report the synthesis of six new compounds containing a 
pyrazino[2,3-b]indolizine or indolizino[2,3-b]quinoxaline core 
(Figure 1, (c)) and, for the first time, a comprehensive study into 
the intermediates involved in the synthesis.  Three of the new 
compounds, 5-(3,5-dimethyl-1H-pyrazol-1-yl)pyrazino[2,3-
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The synthesis of six new compounds incorporating either a pyrazino[2,3-b]indolizine or
indolizino[2,3-b]quinoxaline core are reported in good yield (58-87%). The intermediates for the
key cyclization reaction for one set of compounds (5a – 5c), with a sterically demanding 3,5-
dimethylpyrazole group in the 5 position of the core, were found to be mono-substituted. These
intermediates could be isolated and cyclized by heating under acid-catalyzed conditions. To
further demonstrate the versatility of the chemistry, compounds 6a - 6c were synthesized in 58 –
68% yields. Compounds 5a – 5c are non-planar in solution and the solid-state, while 6a – 6c
have close to planar conformations, pointing to weak hydrogen bonds between the acidic C-Hs
and the adjacent azine nitrogen atoms. The cytotoxicity of the six newly synthesized and three





yl)indolizino[2,3-b]quinoxaline (5b), and 5-(3,5-dimethyl-1H-
pyrazol-1-yl)-8,9-dimethylindolizino[2,3-b]quinoxaline (5c), 
have a 3,5-dimethylpyrazole substituent appended to the 5-
position of the core, while the second set 5-(pyrazin-2-yl)-
pyrrolo[1,2-a:4,5-b]dipyrazine (6a), 5-(pyrazin-2-yl)-
pyrazino[1,2-a]pyrrolo[2,3-b]quinoxaline (6b), and 8,9-dimethyl-
5-(pyrazin-2-yl)-pyrazino[1,2-a]pyrrolo[2,3-b]quinoxaline (6c), 
incorporate a pyrazine ring at this position.  In addition to our 
synthetic studies, for the first time we evaluated the in vitro 




























































Figure 1. (a)  The structures of previously synthesized pyrazino[2,3-
b]indolizine or indolizino[2,3-b]quinoxalines, 1a – 1c; (b) 14-
cyanobenzo[a]indolizino[2,3-b]quinoxaline, 2; pyrazino[2,3-b]indolizine-
2,3,10-tricarbonitrile, 3; variolin B, and the pyrido[3′,2′:4,5]pyrrolo[1,2-
c]pyrimidine core of the variolins, 4; and, (c) the structures of the new 
pyrazino[2,3-b]indolizine or indolizino[2,3-b]quinoxaline compounds 
prepared in this work (5a – 6c). 
 
2. Results and Discussion 
2.1. Synthesis of 5a – 5c 
In previous work, we identified a one-pot synthesis that gives 
access to indolizino[2,3-b]quinoxaline or pyrazino[2,3-
b]indolizine fused heterocycles 1a – 1c.27  To further develop this 
chemistry, we turned our attention to expanding the scope of this 
reaction.  The first set of targets were the compounds bearing an 
electron-rich 3,5-dimethyl-1H-pyrazol-1-yl substituent in the 5-
position of the core 5a – 5c. The first target, compound 5a, was 
ultimately synthesised in two steps from 2-((3,5-dimethyl-1H-
pyrazol-1-yl)methyl)pyridine (7)40 and 8a. Typically, two 
equivalents of the anion of the active methylene compound are 
used in these reactions because it is possible for two routes, via 
the mono- or di-substituted compounds, to be occurring in 
competition in the final cyclization step to yield the final product 
(Scheme 1).  However, in the case of compound 5a, the normal 
conditions did not yield the expected final cyclized product but 
rather the mono-substituted intermediate 9a as the major product 
in 75% yield (Scheme 1).   
After the isolation of 9a, we endeavored to find conditions to 
effect its cyclization to 5a.  Previously,27 we had demonstrated 
that disubstituted intermediates could be cyclized under reflux 
conditions with trifluoroacetic acid (TFA) as a catalyst. In the 
case of 9a, however, the conversion was found to be slow, and a 
1H NMR spectrum of the reaction mixture revealed only 80% 
conversion after 4 days. Hence, 9a was heated in a microwave 
reactor, with TFA and acetonitrile as a solvent, at 140 °C for 90 
minutes.  The 1H NMR spectrum of the reaction mixture revealed 
>99% conversion to product 5a.  The slow conversion of the 
mono-substituted compound 9a can be attributed to the steric 
hindrance about the 3,5-dimethylpyrazolyl ring which hinders 
cyclization and/or further substitution by a second equivalent of 
7.  An X-ray crystal structure of 5a shows a possible origin of 
this steric hindrance, whereby the methyl substituents on the 
pyrazole ring impede access to the adjacent position (C2) by 
incoming nucleophiles (Figure 2). 
The indolizino[2,3-b]quinoxaline compounds 5b and 5c were 
able to be synthesized successfully by the reaction of 7 with 
either 8b or 8c, in good yields of 89% and 73%, respectively.  
For both compounds, spontaneous cyclization of the respective 
intermediate compound to the product was observed during the 
course of the reaction.  In both cases, a small portion of the 
reaction mixture was quenched at room temperature and analyzed 
by 1H NMR spectroscopy.  In the reaction of compound 7 with 
8b, the 1H NMR spectrum revealed cyclized product 5b as the 
major species, along with starting material 7, and aromatic 
signals corresponding to very small quantities of the 
intermediates.  However, in the case of the reaction of 7 with 8c, 
the 1H NMR spectrum revealed cyclized product 5c as the minor 
species, with other peaks in the aromatic region corresponding to 
the proposed intermediates. 
2.2. Investigations of the intermediates 9a – 9c 
To obtain a better understanding of the nature of the 
intermediates present prior to heating, the reaction between 8c 
and 7 was carried out in a 1:1 ratio, and the mixture was 
quenched at −78 °C after 30 min. The major compound in the 
reaction mixture was identified as the mono-substituted 
intermediate 9c, which was isolated and characterized by X-ray 
crystallography (Figure 3).  Once again, the molecular structure 
confirms the presence of steric hindrance in 9c, although it 
should be noted that the 3,5-dimethylpyrazole substituent can be 
directed away from the chlorine atom by rotation about the newly 
formed carbon-carbon bond.  The 1H NMR spectrum of 9c is 
identical to the major intermediate species observed in the 1H 
NMR spectrum of the reaction performed by using 1:2 
equivalents of compounds 8c and 7.  Upon heating the solid 9c 
 3
above its melting point, a color change from colorless to purple 
was observed, indicating cyclization to product 5c. In comparison 
to the pyrazine analogue 9a, the mono-substituted quinoxaline 
compounds require less thermal energy to undergo the 
intermolecular cyclization reaction, and this can occur without 
the need of acid catalysis.  Since the two sets of compounds (9a 
and 9b/9c) possess the same degree of steric hindrance, the 
greater reactivity of compound 9b/9c may be attributed to greater 
resonance stabilization of the reaction intermediates provided by 























































































Figure 2. (a) A perspective view of the X-ray molecular structure of 
compound 9a showing the possible origin of the steric hindrance.  Thermal 
ellipsoids are shown at the 50% probability level.  (b) A space-filling 





Figure 3. (a) A perspective view of the solid-state molecular structure of 
9c.  Thermal ellipsoids are shown at the 50% probability level.  (b) A space-
filling representation alludes to the possibility that the pyrazole ring hinders 
the approach of nucleophiles to C2 of 9c. 
Tetrahedron 4 
 
In summary, the three compounds 5a, 5b, and 5c were 
isolated as red (5a) and purple (5b, and 5c) solids, and gave 
intense red-orange and purple solutions, respectively, upon 
dissolution in dichloromethane, which is indicative of the 
conjugated indolizino[2,3-b]quinoxaline core. 
2.3. Synthesis of 6a – 6c 
The synthesis of compounds 6a – 6c required the 
identification of a reliable procedure to prepare di-2-
pyrazinylmethane (10).  A potential precursor, di-2-
pyrazinylketone (11), is known41 and could be synthesized from 
2-iodopyrazine (12) using n-BuLi in a lithium-halogen exchange 
protocol.42  In order to avoid the unwanted nucleophilic 
substitution of 2-iodopyrazine with the butyl anion, we attempted 
the preparation of ketone 11 by metallation of 12 using 
commercially-available i-PrMgCl or n-BuMgCl43 (Scheme 2) and 
reacting the newly-formed Grignard reagent with methyl ester 13. 
With i-PrMgCl only trace amounts of the desired ketone 11 were 
obtained, while performing the reaction with n-BuMgCl gave the 
ketone in 27% yield, with a major portion of the Grignard 
material isolated as 2-butylpyrazine. A Wolff-Kishner reduction 
on 11 gave diarylmethane 10 in 53% isolated yield. 
An alternative route to 10 involving a one-step reaction which 
proceeds via a lithiation of 2-methylpyrazine was also 
investigated. Based on the synthesis of di-2-pyridylmethane,44 
metallation of 2-methylpyrazine (14) by using LDA,45 and its 
subsequent reaction with 2-chloropyrazine (15), gave 10 directly 
in 25% yield.  The isolated yield of 25% is an improvement on 
the synthesis of 10 by means of the ketone method (ca. 14% 
overall).   
Deprotonation of 10 and subsequent reaction with either 8a, 
8b or 8c gave three new compounds (Scheme 3) possessing 
either an pyrrolo[1,2-a:4,5-b]dipyrazine (6a) or pyrazino[1,2-
a]pyrrolo[2,3-b]quinoxaline (6b and 6c) core, respectively.  The 
propensity of n-BuLi to act as a nucleophile in the presence of 
pyrazine derivatives46 led us to first examine the use of LDA as 
the base.  LDA has been widely used on pyrazine derivatives,45, 
47, 48 however, the isolated yields of 6b and 6c using LDA were 
35% and 36% respectively.  In contrast, when n-BuLi was used 
as the base, the compounds 6a, 6b, and 6c were isolated in much 
improved yields of 58%, 67%, and 69% respectively.  Like 
compounds 5a – 5c, these heterocycles were isolated as red and 
purple solids that gave intense orange and purple solutions upon 
dissolution in chloroform.  
2.4. Solution and solid state structures 
The structures and purity of compounds 5a – 5c and 6a – 6c 
were confirmed by 2D NMR spectroscopy, mass spectrometry 
and elemental analysis.  In the 1H NMR spectrum of compounds 
5a, 5b and 5c, H4 appears significantly upfield relative to 1a – 
1c.27  Therefore, it was deduced that the 3,5-dimethylpyrazolyl 
ring in the 5-position is in a significantly twisted conformation, 
with the π-system of the pyrazolyl ring shielding the H4 atom.  
This differs significantly from what we propose occurs in 
solution for 1a-1c and 6a-6c where the heterocyclic ring in the 5-
position of the core is close to planar and involved in two H-
bonding interactions. 
A single crystal of compound 5b, suitable for X-ray 
crystallography, was obtained by slow evaporation of a 
dichloromethane/diethyl ether solution of 5b.  Compound 5b 
crystallizes in the monoclinic space group P21/c with one 
complete molecule in the asymmetric unit (Figure 4).  As 
observed for other closely related compounds,27 the core of 5b is 
planar.  The conformation of the 3,5-dimethylpyrazolyl ring in 
the solid-state is in agreement with that observed in solution by 
1H NMR spectroscopy.  The twisted conformation, where the 
torsion angle is 58.4°, can be attributed to a steric hindrance 
between the 5′-methyl group of the 3,5-dimethyl pyrazolyl ring 
and H4. 
For the compounds 6a, 6b and 6c, it was expected that the 
pyrazine ring in the 5-position would be close to planar with 
respect to the core, as the position of the H4 atom in the 1H NMR 
spectrum was relatively downfield due to deshielding by the 
adjacent nitrogen atom.  A single crystal X-ray structure 
confirmed this conformation to be present in the solid-state of 6a 
(Figure 5) and 6b (Figure 6).  In the structure of 6a the torsion 
angle for the pendant pyrazine ring is 17.6°, while in the structure 
of 6b the torsion angle is 5.6°.  These conformations are 
consistent with a H-bonding interaction between the acidic C-Hs 



























Scheme 2. i) n-BuMgCl, THF, 0 °C; ii) ethylene glycol, KOH, NH2NH2·H2O; iii) LDA, THF, −78 °C. 
 








Figure 4. (a) A perspective view of the molecular structure of 5b showing 
the planar indolizino[2,3-b]quinoxaline core with thermal ellipsoids at the 
50% probability level. (b) A view of 5b perpendicular to the core showing the 






Figure 5.  (a) A perspective view of 6a, with thermal ellipsoids at the 
50% probability level.  (b) A view of 6a perpendicular to the core showing 





Figure 6.  (a) A perspective view of the molecular structure of 6b 
showing the planar core, with thermal ellipsoids at the 50% probability level.  
(b) A view of 6b perpendicular to the core showing the near planar 
conformation of the pyrazine ring. 
2.5. Biological activity  
Due to the promising biological activity of the variolin family 
of compounds,30 we assessed the biological activity of selected 
compounds against the T98G (human glioblastoma multiforme) 
cell line.  Variolin B has an IC50 of 0.716 µM against the P388 
murine leukemia cell line,30 and both variolin B and 
deoxyvariolin B have been observed to affect cell-cycle 
progression.  The cytotoxicity of our compounds was assessed 
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay49 and cell viability was determined by 
measuring the absorbance of the purple formazan solution at 600 
nm using a microplate reader.  The results are shown below in 
Table 1, with no determination being possible for compound 5c 
which was found to be poorly soluble in the cell culture medium. 
None of the compounds tested exhibited marked cytotoxic 
activity against the T98G cell line, although the pyrrolo[1,2-a:4,5-
b]dipyrazine (6a) and pyrazino[1,2-a]pyrrolo[2,3-b]quinoxaline (6b 
and 6c) derived compounds were found to be the most active 
compounds.  The least active compound, 5a, is the one with the 
smallest core aromatic surface area, and consequently might point to 
some type of DNA intercalation being important in the cytotoxicity 
of this particular set of compounds. 
Table 1.  In vitro cytotoxicity of compounds 1a-1c, 5a, 5b, and 6a-6c in a MTT cytotoxicity assay using the human glioblastoma 
multiforme (T98G) cell line. 
Compound 1a 2a 3a 5a 5b 5c 6a 6b 6c 
Average 
(µM) 
88.8 66.7 72.7 324.0 62.1 NDc 33.8 46.0 36.4 
SEa 8.5 6.2 4.9 34.6 6.7 NDc 5.8 6.5 1.6 
Nb 5 5 5 4 3  3 5 4 
a. SE = standard error. 
b. N= number of cytotoxicity assays run. 
c. ND = not determined due to solubility limitations 
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3. Conclusions 
The syntheses of six fused heterocyclic compounds 5a – 6c 
have been accomplished in good yield.  Due to steric hindrance 
caused by the 3,5-dimethylpyrazole ring, the synthesis of the 
series of compounds 5a – 5c proceeded via cyclization of the 
corresponding isolable mono-substituted intermediates 9a and 9c 
under forcing conditions.  The intermediate 9b cyclizes upon 
warming to room temperature and it was not isolated from the 
reaction mixture.  The synthesis of 6a – 6c required the 
preparation of di-2-pyrazinylmethane (7), which after some 
investigation, was accomplished in 25% isolated yield.  
Thereafter, the synthesis of 6a – 6c proceeded in a facile manner 
to generate the three new compounds in good yields (58-68%). 
Due to steric hindrance, compounds 5a – 5c are non-planar in 
solution and the solid-state, while 6a – 6c have close to planar 
conformations, pointing to H-bonding interactions between the 
acidic C-H groups (H4 and H3’) and the adjacent nitrogen atoms 
in these compounds, as confirmed by NMR spectroscopy and X-
ray crystallography.  The cytotoxicity of these newly synthesized 
compounds and three previously synthesized compounds was 
also assessed.  Despite their structural similarity to variolin B, 
there was no significant cytotoxic activity observed for any of the 
compounds, with 6a, 6b, and 6c being the most active of the 
series.  In future studies, we will utilize their bidentate chelating 
motifs to prepare transition metal complexes which should have 
improved aqueous solubility and cytotoxicity.  Our work on the 
coordination chemistry of these compounds and investigation 
into applications in dye-sensitized solar cells is ongoing and will 
be reported in due course. 
4. Experimental details 
4.1 General experimental 
Melting points were measured on a Gallenkamp melting point 
apparatus and are uncorrected. Elemental analyses were 
performed by the Campbell Microanalytical Laboratory at the 
University of Otago.  Unless otherwise stated, NMR spectra were 
recorded on a Varian 600MHz spectrometer at 23°C using a 5-
mm probe.  1H NMR spectra recorded in CDCl3 were referenced 
relative to the internal standard Me4Si.  When required, one-
dimensional nuclear Overhauser effect correlation spectroscopy 
(1D NOESY), total correlation spectroscopy (TOCSY), rotating 
frame Overhauser effect spectroscopy (ROESY), two-
dimensional correlation spectroscopy (2D COSY), 2D NOESY, 
2D ROESY, heteronuclear multiple quantum coherence 
(HMQC), and heteronuclear multiple bond correlation (HMBC) 
experiments were performed using standard pulse sequences.  
Electrospray (ES) mass spectra were recorded using a Finnigan 
LCQ mass spectrometer.  Infrared spectra were collected on a 
Perkin Elmer Spectrum 100 using a UATR sampling accessory.  
UV-visible absorption spectra were recorded on a Varian Cary 
5000 UV/visible/NIR spectrometer in dichloromethane solutions 
with concentrations of ∼0.25mM. 
Unless otherwise stated, all chemicals were obtained from 
commercials sources and used as received.  Tetrahydrofuran was 
dried by standard literature procedures and distilled fresh from 
sodium/benzophenone, and diisopropylamine was freshly 




yl)methyl)pyridine (7),40 2-iodopyrazine (12),42 and 2-
pyrazinecarboxylate methyl ester (13)52 were prepared according 
to the methods described in the literature. 
4.2 Synthesis 
4.2.1. Di-2-pyrazinylmethane (10). A solution of 2-
methylpyrazine (2.31 mL, 25.2 mmol) in THF (35 mL) was 
added dropwise to freshly prepared LDA (26.0 mmol) in THF 
(15 mL) at −78 °C under an atmosphere of argon. The resulting 
dark red solution was stirred for 1 hour at −78 °C, then cooled to 
−95 °C. 2-Chloropyrazine (1.00 mL, 11.4 mmol) in THF (35 mL) 
was cooled to −78 °C and transferred via cannula to the solution 
of the anion. Once the addition was complete the dark mixture 
was stirred at −95 °C for 5 mins, then the cooling was removed 
and the reaction vessel was allowed to warm to room 
temperature, during which a color change to deep purple was 
observed. After stirring for 15 mins, water (50 mL) was added 
and the mixture was stirred for period of 2 hours during which a 
color change to dark brown was observed. The mixture was 
concentrated under reduced pressure, and repeatedly extracted 
with dichloromethane (5 x 50 mL) until the extracts were almost 
colorless. The organic extracts were combined and dried over 
MgSO4 and the solvent was evaporated under reduced pressure. 
The dark residue was twice extracted by adding hexane to the 
residue and refluxing for a period of 1.5 hours. The extracts were 
combined and evaporated under reduced pressure, yielding a 
yellow crystalline solid, which was sublimed under reduced 
pressure at 110-120 oC (bath temperature) to afford 10 as a pale 
yellow crystalline solid. (0.49 g, 25%), mp: 61-63 °C; νmax (neat, 
cm−1) 3010, 1579, 1520, 1479, 1405; 1H NMR (300 
MHz/CDCl3): δ 8.64 (d, 2H, H3), 8.52 (dd, 2H, J = 2.5 Hz, H5), 
8.47 (d, 2H, J = 2.5 Hz, H6), 4.39 (s, 2H, CH2);  13C NMR (75.4 
MHz/CDCl3): δ 41.8, 143.1, 144.43, 145.2, 154.0; Found: C 62.8, 
H 4.9, N 32.3, C9H8N4 requires: C 62.8, H 4.7, N 32.5%.   
4.2.2. General procedure for the synthesis of 5a-c and 6a-c 
n-BuLi (1.05 equiv.) was added dropwise to a solution of the 
diarylmethane (1 equiv.) in dry THF at −78 °C under an argon 
atmosphere. The solution was stirred for 0.5 hours, followed by 
the dropwise addition of the electrophile (0.49 equiv.) in THF. 
The reaction mixture was slowly allowed to warm to room 
temperature overnight, followed by heating at reflux (16 hours).  
The reaction mixture was quenched with H2O (2 mL) and the 
solvent was removed under reduced pressure. The residue was 
taken up into chloroform or dichloromethane (3 x 50 mL) and 
washed with water (3 x 50 mL). The organic layer was dried over 
MgSO4 and the solvent was removed under reduced pressure.  
4.2.3. 2-Chloro-3-[(3,5-dimethyl-1H-pyrazol-1-yl)(pyridin-2-
yl)methyl]pyrazine (9a). 2-[(3,5-dimethyl-1H-pyrazol-1-
yl)methyl]pyridine (7) (1.05 g, 5.61 mmol), n-BuLi (2.48 mL, 
5.71 mmol) and 2,3-dichloropyrazine (8a) (0.284 mL g, 2.72 
mmol) were combined according to the general procedure. The 
reaction mixture was stirred at room temperature for 4 hours and 
then quenched. The solvent was removed under reduced pressure 
and the dark oil was left to stand for 24 hours, during which time 
the product crystallized. The crystals were separated from the 
oily residue by decanting, and the remainder of the product was 
isolated by adding diethyl ether to the oily mixture and cooling to 
−20 °C which induced further crystallization of 9a. The 
crystalline samples were combined and recrystallized from 
diethyl ether to yield the product as an off-white crystalline solid 
(0.62 g, 75 %). mp 147-149 °C;  νmax (neat, cm−1) 1590, 1557, 
1439, 1381; 1H NMR (600 MHz/CDCl3): δ 2.18 (s, 3H, CH3), 
2.24 (s, 3H, CH3), 5.92 (s, 1H, H4′), 7.02 (d, 1H, J = 7.7 Hz, 
H3′′), 7.05 (s, 1H, CH), 7.24 (dd, 1H, J = 4.8, 7.7 Hz, H5′′), 7.70 
(t, 1H, J = 7.7 Hz, H4′′), 8.31 (d, 1H, J = 2.5 Hz, H5/H6), 8.44 
(d, 1H, J = 2.5 Hz, H5/H6), 8.54 (d, 1H, J = 4.8 Hz, H6′′); 13C 
NMR (151 MHz/CDCl3): δ 11.3, 13.7, 65.2, 106.0, 122.8, 123.0, 
137.1, 140.6, 141.9, 142.7, 148.8, 148.9, 149.4, 152.3, 157.6;  
 7
m/z 264.0 (MH+) (cyclizes);  Found: C 60.1, H 4.7, N 23.5, 
C15H14ClN5 requires: C 60.1, H 4.7, N 23.4%.  
4.2.4. 5-(3,5-Dimethyl-1H-pyrazol-1-yl)pyrazino[2,3-
b]indolizine (5a).  2-Chloro-3-((3,5-dimethyl-1H-pyrazol-1-
yl)(pyridin-2-yl)methyl)pyrazine (0.132 g, 0.440 mmol) was 
dissolved in acetonitrile (9 mL) and TFA (0.5 mL) in a sealed 
vessel and reacted in a CEM Discover S microwave reactor at 
145 °C for 1.5 hours with stirring. The microwave settings were 
150 W, with a maximum pressure of 250 psi. During the course 
of the reaction the pressure was stable at around 50 psi. The 
resulting dark red mixture was neutralized with saturated aqueous 
NaHCO3 solution and extracted with dichloromethane (4 x 15 
mL). The solvent was dried over MgSO4 and removed under 
reduced pressure. The red solid obtained was recrystallized from 
diethyl ether to yield a bright red fluffy solid of 5a (0.09 g, 77%) 
mp: 134-136 °C; νmax (neat, cm−1) 2914, 1633, 1578, 1558, 1487; 
1H NMR (600 MHz/CDCl3) δ 2.22 (s, 3H, Me), 2.34 (s, 3H, Me), 
6.08 (s, 1H, H4′), 6.77 (t, 1H,  J = 6.8 Hz, H2), 7.22 (dd, 1H, J = 
6.8, 9.3 Hz, H3), 7.52 (d, 1H, J = 9.3 Hz, H4), 8.37 (d, 1H, J = 
2.4 Hz, H8), 8.75 (d, 1H, J = 2.4 Hz, H7), δ 8.82 (d, 1H, J = 6.8 
Hz, H1); 13C NMR (151 MHz/CDCl3): δ 11.5, 13.8, 103.4, 105.7, 
110.4, 116.9, 123.8, 127.5, 132.8, 134.3, 134.8, 135.5, 142.5, 
143.2, 149.9; m/z 264.1 (MH+); Found: C 68.6, H 4.9, N 26.8, 
C15H13N5 requires: C 68.4, H 5.0, N 26.6%; λmax/nm: 452 (ε/M−1 
cm−1 4010).  
4.2.5. 5-(3,5-Dimethyl-1H-pyrazol-1-yl)indolizino[3,2-
b]quinoxaline (5b).  2-[(3,5-Dimethyl-1H-pyrazol-1-
yl)methyl]pyridine (7) (0.459 g, 2.45 mmol), n-BuLi (1.11 mL, 
2.50 mmol) and 2,3-dichloroquinoxaline (8b) (0.238 g, 1.20 
mmol) were combined and reacted as described in the general 
procedure. The crude reaction mixture was subject to a standard 
workup with dichloromethane. The crude solid obtained was 
suspended in cold hexane, isolated under reduced pressure, and 
thoroughly washed with cold hexane (4 x 25 mL), to afford the 
product 5b as an purple solid (0.33 g, 89%). mp: 214-216 °C; 
νmax (neat, cm−1) 2917, 1636, 1589, 1540, 1518, 1485; 1H NMR 
(600 MHz/CDCl3): δ 2.28 (s, 3H, Me), 2.38 (s, 3H, Me), 6.13 (s, 
1H, H4′), 6.71 (t, 1H, J = 6.8 Hz, H2), 7.28 (dd, 1H, J = 9.2 Hz, 
6.8 Hz, H3), 7.49 (d, 1H, J = 9.2 Hz, H4), 7.71-7.81 (m, 2H, 
H7/H10), 8.27 (d, 1H, J = 8.2 Hz, H8/H9), 8.31 (d, 1H, J = 8.2 
Hz, H8/H9), 8.94 (d, 1H, J = 6.8 Hz, H1); 13C NMR (151 
MHz/CDCl3): δ 11.6, 13.7, 101.9, 105.8, 109.5, 116.8, 125.2, 
127.1, 128.6, 128.7, 128.9, 130.4, 134.6, 136.0, 137.1, 140.8, 
142.8, 143.3, 149.9;  m/z: 314.3 (MH+);  Found: C 68.8, H 4.8, N 
21.5, C19H15N5·H2O requires: 68.85, 5.2, 21.1%; λmax/nm: 527 
(ε/M−1 cm−1 4620).  
4.2.6. 5-(3,5-Dimethyl-1H-pyrazol-1-yl)-8,9-
dimethylindolizino[2,3-b]quinoxaline (5c) 2-[(3,5-Dimethyl-1H-
pyrazol-1-yl)methyl]pyridine (7) (0.647 g, 3.46 mmol), n-BuLi 
(1.50 mL, 3.50 mmol) and 2,3-dichloro-6,7-dimethylquinoxaline 
(8c) (0.383 g, 1.69 mmol) were combined and reacted in the 
manner described in the general procedure. The crude reaction 
mixture was subjected to a standard work-up with 
dichloromethane. The solid obtained was suspended in cold 
hexane, isolated by filtration, and thoroughly washed with cold 
hexane (4 x 25 mL) to afford 5c as a purple solid (0.42 g, 73%). 
mp: 201-203 °C; νmax (neat, cm−1, cm−1) 2910, 1634, 1587, 1536, 
1511, 1488; 1H NMR (600 MHz/CDCl3): δ 2.28 (s, 3H, Me′), 
2.35 (s, 3H, Me′), 2.53 (s, 3H, Me), 2.55 (s, 3H, Me), 6.10 (s, 1H, 
H4′), 6.67 (t, 1H, J = 6.8 Hz, H2), 7.22 (dd, 1H, J = 9.3 Hz, 6.8 
Hz, H3), 7.45 (d, 1H, J = 9.3 Hz, H4), 7.98 (s, 1H, H7/H10), 8.04 
(s, 1H, H7/H8), 8.88 (d, 1H, J = 6.8 Hz, H1); 13C NMR (151 
MHz/CDCl3): δ 11.6, 13.8, 20.3, 20.4, 102.1, 105.7, 109.1, 116.7, 
125.0, 127.4, 127.9, 129.5, 134.2, 135.5, 136.2, 137.8, 139.2, 
139.6, 142.4, 142.6, 149.7; m/z: 342.2 (MH+); Found: C 73.0, 
H 5.8, N 20.1. C21H19N5·¼H2O requires: C 72.9, H 5.7, N 
20.25%; λmax/nm: 524 (ε/M−1 cm−1 4800).  
4.2.7. 2-Chloro-3-[(3,5-dimethyl-1H-pyrazol-1-yl)(pyridin-2-
yl)methyl]-6,7-dimethylquinoxaline (9c).  2-[(3,5-Dimethyl-1H-
pyrazol-1-yl)methyl]pyridine (7) (0.397 g, 2.12 mmol), n-BuLi 
(0.962 mL, 2.10 mmol) and 2,3-dichloro-6,7-
dimethylquinoxaline (0.438 g, 1.93 mmol) were combined as 
described in the general procedure. The reaction mixture was 
allowed to stir at −78 °C for 0.5 hours, and then quenched with 
EtOH (20 mL). The solvent was removed under reduced pressure 
and the residue was purified by column chromatography eluting 
with 9:1 dichloromethane/ethyl acetate to afford a white solid 
(0.25 g, 34%). mp: 176-179 °C; νmax (neat, cm−1) 1590, 1555, 
1474, 1436; 1H NMR (600 MHz/CDCl3): δ 2.15 (s, 3H, CH3), 
2.25 (s, 3H, CH3), 2.40 (s, 3H, CH3), 2.46 (s, 3H, CH3), 5.93 (s, 
1H, H4′), 7.13 (d, 1H, J = 7.7 Hz, H3′′), 7.18 (s, 1H, CH), 7.25 
(dd, 1H, J = 4.8, 7.7 Hz, H5′′), 7.67 (s, 1H, H5/H10), 7.70-7.75 
(m, 3H, H4′′, H5/H10), 8.55 (d, 1H, J = 4.8 Hz, H6′′); 13C NMR 
(151 MHz/CDCl3): δ 11.4, 13.7, 20.1, 20.4, 66.2, 106.1, 122.7, 
123.4, 127.0, 128.8, 136.9, 139.4, 140.2, 140.4, 140.6, 141.7, 
146.3, 148.5 148.7, 149.9, 157.9; m/z 342.0 (MH+) (cyclizes);  
Found: C 66.8, H 5.3, N 18.6. C21H20ClN5 requires: C 66.7, H 
5.4, N 18.5%.  
4.2.8. 5-(Pyrazin-2-yl)-pyrrolo[1,2-a:4,5-b]pyrazine (6a).  Di-
2-pyrazinylmethane (10) (0.244 g, 1.41 mmol) in THF (20 mL), 
n-BuLi (0.740 mL, 1.43 mmol) and 2,3-dichloropyrazine (8a) 
(0.0730 mL, 0.698 mmol) in THF (20 mL) were combined and 
reacted in the manner described. The reaction mixture was stirred 
at room temperature for 16 hours then heated at reflux for 20 
hours. The reaction mixture was quenched with methanol (2 mL). 
Upon cooling to room temperature a red precipitate formed. The 
solvent was removed under reduced pressure and the crude 
product was isolated as described in the general procedure using 
CHCl3 as the extracting solvent. The isolated product was 
recrystallized from THF to afford the title compound 6a as an 
orange solid (0.10 g, 58%). mp: 262 °C; νmax (neat, cm−1) 3098, 
1576, 1542, 1504, 1482, 1467; 1H NMR (300 MHz/CDCl3): δ 
7.97 (d, J = 4.8 Hz, 1H, H6′), 8.47 (d, J = 2.4 Hz, 1H, H1), 8.59 
(d, J = 2.3 Hz, 1H, H8), 8.65-8.68 (m, 2H, H2/H5′), 9.00 (d, J = 
2.3 Hz, 1H, H7), 10.18 (d, J = 1.5 Hz, 1H, H4), 10.45 (d, J = 1.7 
Hz, 1H, H3′); 13C NMR (151 MHz/CDCl3): 102.7, 115.9, 128.0, 
130.6, 134.3, 136.3, 137.9, 141.4, 143.7, 144.4, 144.6, 149.4, 
149.4;  m/z 249.2 (MH+); Found: C 61.9, H 3.4, N 33.3. 
C13H8N6·¼H2O requires: C 61.8, H 3.4, N 33.3%; λmax/nm: 464 
(ε/M−1 cm−1 4200).  
4.2.9. 5-(Pyrazin-2-yl)-pyrazino[1,2-a]pyrrolo[2,3-
b]quinoxaline (6b).  Di-2-pyrazinylmethane (10) (0.220 g, 1.27 
mmol) in THF (20 mL), n-BuLi (0.674 mL, 1.28 mmol) and 2,3-
dichloroquinoxaline (8b) (0.123 g, 0.618 mmol) in THF (15 mL) 
and reacted in the manner described. After stirring at room 
temperature, the reaction mixture was warmed to 50 °C for 1 
hour and then quenched. The purple reaction mixture was 
subjected to the standard work-up (using CHCl3) and yielded a 
dark solid which was isolated by filtration and repeatedly washed 
with diethyl ether until the washings were clear. This afforded the 
title compound as a purple solid (0.11 g, 58%). Sublimes 280-
283 °C; νmax (neat, cm−1) 3074, 1577, 1546, 1521, 1509, 1466; 1H 
NMR (600 MHz/CDCl3): δ 7.86 (dd, J = 7.4, 7.8 Hz, 1H, 
H8/H9), 7.91 (dd, J = 7.4, 7.8 Hz, 1H, H8/H9), 7.95 (d, J = 4.7 
Hz, 1H, H1), 8.29 (d, J = 8.4 Hz, 1H, H7/H10), 8.43 (d, J = 8.4 
Hz, 1H, H7/H10), 8.48 (s, 1H, H6′), 8.67 (s, 1H, H5′), 8.76 (d, J 
= 4.7 Hz, 1H, H2), 10.48 (s, 1H, H3′), δ 10.50 (s, 1H, H4); 13C 
NMR (151 MHz/CDCl3): 101.1, 116.8, 127.2, 128.9, 129.0, 
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129.5, 129.7, 134.6, 135.4, 138.2, 138.5, 141.1, 143.7, 144.0, 
144.5, 149.5, 149.6; m/z: 298.9 (MH+);  Found: C 67.9, H 3.4, N 
28.4. C17H10N6 requires: C 68.4, H 3.4, N 28.2%;  λmax/nm: 536, 
570 (ε/M−1 cm−1 4760, 4200). 
4.2.10. 8,9-Dimethyl-5-(pyrazin-2-yl)-pyrazino[1,2-
a]pyrrolo[2,3-b]quinoxaline (6c).  Di-2-pyrazinylmethane (10) 
(0.224 g, 1.30 mmol) in THF (20 mL), n-BuLi (0.576 mL, 1.32 
mmol) and 6,7-dimethyl-2,3-dichloroquinoxaline (8c) (0.140 g, 
0.616 mmol) in THF (15 mL) were combined and reacted in the 
manner described. The purple reaction mixture was worked-up as 
described in the general procedure, yielding a dark solid which 
was isolated by filtration and repeatedly washed with diethyl 
ether until the washings were clear. This afforded the title 
compound as a purple solid (0.14 g, 69%). Sublimes 278-280 °C; 
νmax (neat, cm−1) 2919, 1577, 1540, 1507, 1491, 1464; 1H NMR 
(600 MHz/CDCl3) 2.57 (s, 3H, Me), 2.58 (s, 3H, Me), 7.89 (d, 
1H, J = 4.8 Hz, H1), 7.94 (s, 1H, H7/H10), 8.08 (s, 1H, H7/H10), 
8.45 (d, 1H, J = 2.5 Hz, H6′), 8.64 (s, 1H, H5′), 8.67 (d, 1H, J = 
4.8 Hz, H2), 10.40 (s, 1H, H3′), 10.41 (s, 1H, H4); 13C NMR 
(151 MHz/CDCl3): δ 20.5, 20.6, 100.9, 116.7, 127.0, 127.4, 
128.2, 133.7, 134.9, 137.3, 137.5, 140.0, 140.4, 140.9, 143.1, 
143.6, 144.4, 149,4, 149.6; Found: C 66.2, H 4.3, N 24.6. 
C19H14N6·H2O requires: C 66.3, H 4.3, N 24.6.  m/z: 327.0 
(MH+);  λmax/nm: 531, 564 (ε/M−1 cm−1 4680, 3800).  
4.3. Cell line 
T98G human glioblastoma multiforme cells were purchased 
from the ATCC. The cells were maintained as a monolayer in 
minimum essential medium (MEM), supplemented with 10% 
fetal bovine serum, penicillin (100 units/mL), streptomycin (100 
g/mL) and L-glutamine (2.5 mM), at 37 °C in a humidified 5% 
CO2 atmosphere.   
4.4. Cytotoxicity assays 
Cytotoxicity was assessed using the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay.49 Cells were 
harvested with trypsin (0.1% v/v), and cell pellets were isolated 
by centrifugation. Cells were then re-suspended to single cells 
suspension, cell numbers counted using a Haemocytometer 
counter (Weber) and then seeded at a density of 1 × 104 cells/well 
in 96-well plates, in 100 μL growth medium and allowed to 
adhere overnight at 37 °C. Cells were incubated at 37 °C in a 
humidified atmosphere of 5% CO2 in the presence of compounds 
1a – 1c, 5a, 5b and 6a – 6c, and vehicle (control). Serial dilutions 
(1:2 and 1:10) of compound solution in cell medium were added 
to wells in triplicate. Compounds were tested at a concentration 
range prescribed by the limits of compound solubility and that 
produced a sigmoidal cytotoxic response.  After 72 h of drug 
exposure, MTT solution in PBS (20 μL, 0.25% w/v) was added to 
each well and the incubation continued for 4 h.  Culture medium 
and excess MTT solution were removed and the resulting 
reduced formazan crystals dissolved by addition of 150 μL 
DMSO.  
Cell viability was determined by measuring the absorbance of 
the purple formazan solution at 600 nm using a Victor3V 
microplate reader (Perkin Elmer). All readings were corrected for 
absorbance from negative control and wells containing medium 
alone. The level of purple intensity was expressed relative to the 
corresponding control as percent viability. Corresponding IC50 
values for each of the compounds tested were then determined at 
the dose required to induce a 50% decrease in cell viability from 
sigmoidal dose-response curves produced in GraphPad Prism 5 
(Version 5.04). Experiments were repeated at least three times for 
each compound and all IC50 values are reported with standard 
errors.  
4.5. Crystallography 
Crystals were mounted under paratone-N oil on a plastic loop.  
X-ray diffraction data were collected with (i) Mo-Kα radiation (λ 
= 0.7107 Å) using an Oxford Diffraction X-calibur single crystal 
X-ray diffractometer at 150(2) K (structures 9a, 9c, and 6b), or 
(ii) synchrotron radiation (λ = 0.7107 Å) at 150(2) K using the 
Protein Micro-crystal and Small Molecule X-ray Diffraction 
beam line (MX2) at the Australian Synchrotron (structures of 5b, 
and 6a).53  Data sets were corrected for absorption using a multi-
scan method, and structures were solved by direct methods using 
SHELXS-9754 and refined by full-matrix least squares on F2 by 
SHELXL-97,55 interfaced through the program X-Seed.56  In 
general, all non-hydrogen atoms were refined anisotropically and 
hydrogen atoms were included as invariants at geometrically 
estimated positions, unless specified otherwise in additional 
details below.  Figures were produced using the program POV-
Ray,57 interfaced through the program X-Seed.  Publication 
materials were prepared using the program CIFTAB.58  Details of 
data collections and structure refinements are given below.  
CCDC 818294 – 818298 contain the supplementary 
crystallographic data for this structure.  This data can be obtained 
free of charge from The Cambridge Crystallographic Data Centre 
via www.ccdc.cam.ac.uk/data_request/cif.  A summary of the 
crystallographic data and structure refinements are given in Table 
2. 
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